Tolerability of favipiravir therapy in critically ill patients with COVID‐19: A report of four cases

Dauby, Nicolás; Praet, Serge Van; Vanhomwegen, Charlotte; Veliziotis, Ioannis; Konopnicki, Déborah; Roman, Alain

doi:10.1002/jmv.26488

Cited by 14 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The case reports published so far indicate that the higher doses of favipiravir are required to mellow down the higher viral loads. 43 A pharmacokinetic study of Favipiravir performed on seven patients indicated that the favipiravir concentration was much less in critically ill SARS-CoV2 patients than in the healthy volunteers. 21,44 This finding is crucial as dose optimization may lead to favorable results with favipiravir in COVID-19.…”

Section: Discussionmentioning

confidence: 99%

<p>Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database</p>

Kaur¹,

Charan²,

Dutta³

et al. 2020

IDR

View full text Add to dashboard Cite

Background COVID-19 caused by SARS-CoV-2 virus emerged as an unprecedented challenge to discover effective drugs for its prevention and cure. Hyperinflammation-induced lung damage is one of the poor prognostic indicators causing a higher rate of morbidity and mortality of COVID-19 patients. Favipiravir, an antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety. Thus, the present study was undertaken to evaluate the adverse drug events (ADEs) reported in the WHO pharmacovigilance database. Methods This study analyzed all suspected ADEs related to favipiravir reported from 2015. The reports were analyzed based on age, gender, and seriousness of ADEs at the System Organ Classification (SOC) level and the individual Preferred Term (PT) level. Results This study is based on 194 ADEs reported from 93 patients. Most frequent ADEs suspected to be caused by the favipiravir included increased hepatic enzymes, nausea and vomiting, tachycardia, and diarrhea. Severe and fatal ADEs occurred more frequently in men and those over the age of 64 years. Blood and lymphatic disorders, cardiac disorders, hepatobiliary disorders, injury poisoning, and procedural complications were more common manifestations of severe ADEs. Conclusion This study revealed that favipiravir appears to be a relatively safe drug. An undiscovered anti-inflammatory activity of favipiravir may explain the improvement in critically ill patients and reduce inflammatory markers. Currently, the data is based on very few patients. A more detailed assessment of the uncommon ADEs needs to be analyzed when more information will be available.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database</p>

Kaur¹,

Charan²,

Dutta³

et al. 2020

IDR

View full text Add to dashboard Cite

show abstract

“…After favipiravir administration, the clinical status improved in 74 cases, worsened in 48 cases (with 21 deaths), and was unclear in 20 cases. The reported side effects were hyperuricemia Hosoba et al, 2020;Ono et al, 2020;Takoi et al, 2020 ), fever ( Koba et al, 2020 ;Kurita et al, 2020 ;Takoi et al, 2020 ), lymphocytosis ( Dauby et al, 2021 ), eosinophilia ( Takoi et al, 2020 ), lymphocytopenia ( Atallah et al, 2020 ), hepatotoxicity ( Hosoba et al, 2020 ;Takumida et al, 2021 ;Yamazaki et al, 2021 ), nephrotoxicity ( Nasa et al, 2021 ), acute pancreatitis ( Khan et al, 2021 ), wood's lamp fluorescence on nails and hair, and nausea ( Aslan Kayiran et al, 2021 ).…”

Section: Case Reportsmentioning

confidence: 99%

The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies

Hung

Ghula

Aziz

et al. 2022

International Journal of Infectious Diseases

View full text Add to dashboard Cite

“…Favipiravir inhibits RNA polymerase, which is responsible for gene replication in RNA virus cells, and thereby prevents viral replication [ 9 ]. In vitro, favipiravir has moderate antiviral activity against SARS-CoV-2, an RNA virus, and is predicted to be a COVID-19 therapeutic agent [ 10 ]. Elevated blood uric acid levels are a common favipiravir side effect; however, levels rapidly return to normal after the drug is stopped, and most studies found few hyperuricemia symptoms [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient

Jadeja¹,

Patel²

2021

Cureus

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 has had an indelible effect, with 153,738,171 cases recorded globally as per the World Health Organization's dashboard. The medical establishment is racing to find repurposed medications that can be successful against this novel coronavirus due to a shortage of new drugs to treat the disease. Favipiravir, an antiviral drug originally developed for influenza, is one of the drugs that has recently received a lot of attention, particularly in India. Here, we present a case of favipiravir-induced drug fever in a young adult coronavirus disease 2019 patient.

show abstract

Tolerability of favipiravir therapy in critically ill patients with COVID‐19: A report of four cases

Cited by 14 publications

References 12 publications

<p>Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database</p>

<p>Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database</p>

The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies

Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient

Contact Info

Product

Resources

About